Facebook
Twitter
LinkedIn
ForwardAUA Annual Meeting Highlights: Advanced Prostate Cancer (2017)
The urologist’s role in treating advanced prostate cancer patients continues to expand as the therapeutic options increase. Since 2010, five therapies have been approved by the Food and Drug Administration (FDA) with survival benefit. It is critical that urologists remain engaged and knowledgeable on the management of CRPC in the contemporary setting of a multitude of new agents becoming available to treat patients.
Target Audience
- Urologists
- Urologists in training
- Non-physician providers involved in urology.
Learning Objectives
Course 002IC: Chemotherapy and Immunotherapy Options for Genitourinary Malignancies
Learning Objectives:
At the conclusion of this CME activity, participants should be able to:
- Obtain familiarization with standard of care chemotherapy regimens for genitourinary malignancies
- Obtain familiarization with newer immunotherapy options in the treatment of genitourinary malignancies
- Enhance the identification and management of toxicities with relation to these agents
- Identify the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies
Course 068IC: Prostate Cancer Update 2017
Learning Objectives:
At the conclusion of this CME activity, participants should be able to:
- Cite important new publications in this field during the past year
- Identify the relative strengths and weaknesses of the reports
- Appraise how new studies relate to the existing state-of-the-art in clinical practice
- Analyze whether they and their colleagues should consider changing their practice based on the new information
Course 076IC: Novel Agents and Concepts in the Management of Hormone Naïve and Castration-Resistant Prostate Cancer
Learning Objectives:
At the conclusion of this CME activity, participants should be able to:
- Diagnose castrate resistant prostate cancer (CRPC) and have a working knowledge of treatments and the proper order for administration
- Manage CRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy
- Analyze the mechanism of action and risks/benefits of using systemic agents in the treatment of CRPC
- Describe the bone-targeted, radiopharmaceutical agent, RADIUM-223 and its sequencing
- Review the new generation antiandrogen agent, Enzalutamide and its sequencing
Course 086IC: AUA Guideline: Castration-Resistant Prostate Cancer Update
Learning Objectives:
At the conclusion of this CME activity, participants should be able to:
- Identify the active agents and their mechanism of action in the management of mCRPC
- Analyze the evidence and outcomes on the treatment of CRPC as outlined in the AUA guidelines and subsequent amendments
- Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice
- Understand the sequencing and indications for active treatment with approved agents in the management of mCRPC
Course 089IC: Management of Prostate Cancer: A Cast Based Approach with Emphasis on Integrating New Molecular Diagnostics into Clinical Practice
Learning Objectives:
At the conclusion of this CME activity, participants should be able to:
- Design appropriate screening strategies based on individual demographics, risk factors, and PSA history and to incorporate new biomarkers into routine clinical practice
- Distinguish and understand the use of new molecular and genomic based tests for decisions on initial and re-biopsy, and choosing and following men on surveillance
- Appraise the role of surveillance, focal therapy, surgery, and various forms of radiation therapy in patients with low and intermediate risk disease, including adjuvant and salvage radiation
- Enumerate and contrast the benefits and drawbacks of surgery vs. radiation-based approaches for the management of high risk localized disease
- Describe new therapeutic agents for the management of castrate resistant disease and outline a coherent strategy for their use
Urologic Care for the Advanced Practice Provider: Advanced Prostate Cancer
Learning Objectives:
At the conclusion of this CME activity, participants should be able to:
- Describe at least 3 treatment options and side effect management for men with advanced prostate cancer.
Course 002IC: Chemotherapy and Immunotherapy Options for Genitourinary Malignancies
Costas D. Lallas, MD, FACS, Course Director
Vice Chair and Professor of Urology
Thomas Jefferson University Hospital
Philadelphia, PA
Disclosures: Nothing to disclose
Anne E. Calvaresi, MSN, CRNP
Nurse Practitioner, Urologic Oncology
Thomas Jefferson University
Philadelphia, PA
Disclosures: Nothing to disclose
Edouard J. Trabulsi, MD, FACS
Professor and Vice Chair, Department of Urology
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, PA
Disclosures: Centocor: Consultant or Advisor, Meeting Participant or Lecturer; Amgen: Consultant or Advisor, Meeting Participant or Lecturer; Dendreon: Consultant or Advisor, Meeting Participant or Lecturer; Medivation: Consultant or Advisor, Meeting Participant or Lecturer; Photocure: Consultant or Advisor; GenomeDx: Consultant or Advisor
Course 068IC: Prostate Cancer Update 2017
William J. Catalona, MD, Course Director
Professor, Department of Urology
Director, Clinical Prostate Cancer Program
Northwestern University
Chicago, IL
Disclosures: Beckman Coulter Incorporated: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Beckman-Coulter Incorporated: Consultant or Advisor, Scientific Study or Trial , Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; deCODE Genetics: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; OHMX: Consultant or Advisor, Owner, Product Development; Nanosphere: Consultant or Advisor , Consultant or Advisor; OHMX: Consultant or Advisor, Scientific Study or Trial, Owner, Product Development
Douglas M. Dahl, MD, FACS
Chief, Division of Urologic Oncology
Associate Professor of Urology
Harvard Medical School
Boston, MA
Disclosures: Nothing to disclose
Stanley L. Liauw, MD
Associate Professor, Radiation Oncology
University of Chicago
Chicago, IL
Disclosures: Nothing to disclose
Stacy Loeb, MD, MSc
Assistant Professor, Department of Urology and Population Health
New York University
New York, NY
Disclosures: Sanofi: Meeting Participant or Lecturer; Bayer: Consultant or Advisor, Meeting Participant or Lecturer; MDx Health: Meeting Participant or Lecturer; Armune BioScience, Inc.: Consultant or Advisor; Minomic: Meeting Participant or Lecturer; Boehringer Ingelheim: Meeting Participant or Lecturer; GenomeDx Biosciences: Consultant or Advisor; Astellas: Meeting Participant or Lecturer
Robert B. Nadler, MD
Professor, Department of Urology
Northwestern University Chicago, IL
Disclosures: Nothing to disclose
Russell Szmulewitz
Assistant Professor of Medicine, Section of Hematology/Oncology
University of Chicago
Chicago, IL
Disclosures: Pfizer: Consultant or Advisor; Dendreon: Consultant or Advisor; Genentech: Scientific Study or Trial; Exelixis: Consultant or Advisor; Abbvie: Scientific Study or Trial; Incyte: Scientific Study or Trial; Astellas: Scientific Study or Trial
Course 076IC: Novel Agents and Concepts in the Management of Hormone Naïve and Castration-Resistant Prostate Cancer
Judd W. Moul, MD, FACS, Course Director
Professor of Surgery
Duke University
Durham, NC
Disclosures: Astra Zeneca: Scientific Study or Trial; Sanofi-Aventis: Health Publishing, Meeting Participant or Lecturer; Dendreon: Consultant or Advisor, Meeting Participant or Lecturer; Theralogix: Consultant or Advisor; Ferring Pharmaceuticals Inc: Consultant or Advisor, Meeting Participant or Lecturer; Amgen: Meeting Participant or Lecturer; Medivation-Astellas: Consultant or Advisor; Janssen- J and J: Consultant or Advisor, Meeting Participant or Lecturer; Myriad Genetics Inc: Consultant or Advisor, Meeting Participant or Lecturer; IRIS/Arista Molecular: Meeting Participant or Lecturer, Scientific Study or Trial; Bayer: Consultant or Advisor; Genomic Health: Meeting Participant or Lecturer; Novartis: Consultant or Advisor
Lawrence I. Karsh, MD, FASC
Director, Clinical Research Department
The Urology Center of Colorado
Denver, CO
Disclosures: Astellas: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Dendreon: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Bayer: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Janssen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Medivation: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Genomic Health: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Myriad: Consultant or Advisor, Scientific Study or Trial; Swan Valley Medical: Consultant or Advisor, Investment Interest; Amgen: Scientific Study or Trial; Heat Biologics: Scientific Study or Trial; Bavaria Nordic Immunotherapy: Consultant or Advisor, Scientific Study or Trial; MDxHealth: Scientific Study or Trial; Lawrence Karsh: Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial, Investment Interest; Spectrum Pharmaceuticals: Consultant or Advisor, Scientific Study or Trial; FKD: Scientific Study or Trial; Pfizer: Consultant or Advisor; Sanofi: Consultant or Advisor; Tolmar: Consultant or Advisor; Ferring: Consultant or Advisor; Abbvie: Consultant or Advisor; Argos: Consultant or Advisor, Scientific Study or Trial; Astra-Zeneca: Consultant or Advisor; Augmenix: Consultant or Advisor, Scientific Study or Trial; Precision Biopsy: Consultant or Advisor, Scientific Study or Trial; Takeda: Consultant or Advisor, Scientific Study or Trial; Tokai: Consultant or Advisor, Scientific Study or Trial; 3D BIopsy: Consultant or Advisor, Scientific Study or Trial; GenomeDx BIosciences: Consultant or Advisor, Scientific Study or Trial; Precision Med: Scientific Study or Trial
Christopher Sweeney, MD
Medical Oncologist, Medical Oncology
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Nothing to disclose
Course 086IC: AUA Guideline: Castration-Resistant Prostate Cancer Update
Michael Cookson, MD, MMHC, FACS, Course Director
Professor and Chair, Department of Urology
University of Oklahoma
Oklahoma City, OK
Disclosures: Endo: Consultant or Advisor, Scientific Study or Trial; Spectrum: Consultant or Advisor; GE Healthcare: Consultant or Advisor, Scientific Study or Trial; Myriad: Consultant or Advisor; US HIFU: Consultant or Advisor; Covidien: Consultant or Advisor, Scientific Study or Trial; Photocure: Meeting Participant or Lecturer; Myriad: Consultant or Advisor; Astellas/Medivation: Meeting Participant or Lecturer; PersonalizeDx, an Abbott Company: Consultant or Advisor; Sanofi US Services, Inc.: Consultant or Advisor; Janssen: Meeting Participant or Lecturer; Bayer: Meeting Participant or Lecturer, Scientific Study or Trial; MDxHealth, INc.: Consultant or Advisor; Bayer HealthCare LLC: Consultant or Advisor; Astellas: Consultant or Advisor; Altor Bioscience Cooperation: Consultant or Advisor; Photocure: Consultant or Advisor; TesoRx Pharma LLC: Consultant or Advisor; MDx Health: Consultant or Advisor; MDxHealth: Consultant or Advisor; Janssen Biotech, Inc.: Consultant or Advisor; CiCloMed: Consultant or Advisor; Altor Bioscience Corp.: Consultant or Advisor; Photocure: Meeting Participant or Lecturer, Scientific Study or Trial; Takeda Pharmaceutical: Meeting Participant or Lecturer; Myovant Sciences: Consultant or Advisor; Genomic Health: Consultant or Advisor; MDxHealth: Consultant or Advisor; Pacific Edge Diagnostics USA: Consultant or Advisor
William Lowrance, MD, FACS, MPH
Urologic Oncologist
University of Utah, Huntsman Cancer Institute
Salt Lake City, UT
Disclosures: Myriad Genetics: Scientific Study or Trial; Genome Dx: Scientific Study or Trial; Argos: Scientific Study or Trial; Stream Dx: Investment Interest
Adam S. Kibel, MD, FACS
Chief, Urologic Surgery, Brigham and Women’s Hospital
Chief, Urologic Surgery, Dana-Farber Cancer Institute
Professor, Department of Surgery, Harvard University Medical School
Chairman, Harvard Urology Residency Program
Co-Leader, Prostate Cancer Program, Dana-Farber/Harvard Cancer Center
Boston, MA
Disclosures: Dendreon: Consultant or Advisor, Meeting Participant or Lecturer; Sanofi-Aventis: Consultant or Advisor, Scientific Study or Trial; National Cancer Institute: Consultant or Advisor; Specrum: Consultant or Advisor; Myriad Genetics: Consultant or Advisor; Genomic Health: Consultant or Advisor; MTG: Consultant or Advisor; Profound: Consultant or Advisor; Dendreon: Consultant or Advisor
Course 089IC: Management of Prostate Cancer: A Cast Based Approach with Emphasis on Integrating New Molecular Diagnostics into Clinical Practice
Eric A. Klein, MD, Course Director
Professor of Surgery, Lerner College of Medicine
Chairman, Glickman Urological and Kidney Institute
Cleveland Clinic
Cleveland, OH
Disclosures: GenomeDx Biosciences: Consultant or Advisor, Scientific Study or Trial; Genomimc Health: Consultant or Advisor; Berg: Consultant or Advisor; Cellanyx: Consultant or Advisor
Andrew Stephenson, MD
Director, Center of Urologic Oncology
Cleveland Clinic
Cleveland, OH
Disclosures: Amgen: Consultant or Advisor, Meeting Participant or Lecturer; Myriad Biosciences: Consultant or Advisor; Janssen: Meeting Participant or Lecturer; Genomic Health: Consultant or Advisor; Astellas: Consultant or Advisor, Meeting Participant or Lecturer; Dendreon: Consultant or Advisor; Genomic Health: Consultant or Advisor, Meeting Participant or Lecturer
Urologic Care for the Advanced Practice Provider: Advanced Prostate Cancer
Heather Schultz, RN, MSN, NP-C, Course Co-Director
Nurse Practitioner
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC
Disclosures: SUNA: Meeting Participant or Lecturer
Kenneth Mitchell, MPAS, PAC, Course Co-Director
Physician Assistant
Meharry Medical College
Nashville, TN
Disclosures: Nothing to disclose
Mary Dunn, RN, MSN, OCN, NP-C
Adult Nurse Practitioner
University of North Carolina at Chapel Hill
Chapel Hill, NC
Disclosures: Nothing to disclose
Planner Disclosures
Education Council
Manoj Monga, MD, FACS
Director, Center for Endourology & Stone Disease
Cleveland Clinic
Cleveland, OH
Disclosures: US Endoscopy: Consultant or Advisor; Thermadex: Consultant or Advisor; Percuvision: Consultant or Advisor; Histosonics: Consultant or Advisor; Taris Biomedical: Scientific Study or Trial; Xenolith: Scientific Study or Trial; Cook Urological: Meeting Participant or Lecturer; Mission Pharmacal: Meeting Participant or Lecturer; Coloplast: Consultant or Advisor; Olympus: Consultant or Advisor; Bard: Consultant or Advisor; Fortec: Other: Quality Assurance; Endourology Society: Leadership Position; Indian American Urological Association: Leadership Position; Ohio Urological Society: Leadership Position; Journal of Endourology: Health Publishing; Indian Journal of Urology: Health Publishing; Brazilian Journal of Urology: Health Publishing; Practical Reviews in Urology: Health Publishing; CMS SCIP - Representative for AUA: Leadership Position
Victor W. Nitti, MD
Professor, Department of Urology
Professor, Department of Obstetrics and Gynecology
Director, Female Pelvic Medicine and Reconstructive Surgery
Vice Chair, Department of Urology
NYC School of Medicine
New York, NY
Disclosures: Astellas: Health Publishing, Scientific Study or Trial; Ethicon: Consultant or Advisor; Allergan: Health Publishing, Scientific Study or Trial; Medtronic: Consultant or Advisor; Allergan: Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Pfizer: Health Publishing, Consultant or Advisor; Coloplast: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Coloplast: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Uroplasty: Consultant or Advisor; American Medical Systems: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Astellas: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Pfizer: Consultant or Advisor; Ipsen: Consultant or Advisor; Ono: Consultant or Advisor; Theracoat: Consultant or Advisor; Pneumoflex: Consultant or Advisor; Pfizer: Consultant or Advisor; Cook Myosite: Scientific Study or Trial; Medtronic: Scientific Study or Trial
Brant Inman, MD, MS
Associate Professor, Surgery
Vice Chief, Urology
Duke Cancer Institute of Duke University
Durham, NC
Disclosures: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Ferring Pharmaceuticals: Consultant or Advisor; Genentech Inc: Scientific Study or Trial; Pfizer: Other: Sponsored educational forum; Combat Medical: Consultant or Advisor, Scientific Study or Trial; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisor; Taris Biomedical: Consultant or Advisor; AstraZeneca: Consultant or Advisor; BioCancell: Consultant or Advisor; Nucleix: Scientific Study or Trial
Method of Participation
To claim CME credit/hours of participation, the learner must complete a pretest, read the overview of courses 002IC, 068IC, 076IC, 086IC, 089IC and Urologic Care for the Advanced Practice Provider, complete the posttest, passing with 80% accuracy and submit the evaluation
Estimated time to complete this activity: 1.25 hours
Release Date: October, 2017
Expiration Date: October, 2018
Accreditation Statement
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American Urological Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
If you have already received credit for this course by attending it or watching it live you cannot receive additional credit.
Other Learners
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
This eduring material credit is valid only for content reformatted from courses 002IC, 068IC, 076IC, 086IC, 089IC and Urologic Care for the Advanced Practice Provider.
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Acknowledgements
The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:
AbbVie;
Astellas;
Bayer HealthCare Pharmaceuticals Inc.;
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC;
Medivation, Inc., a Pfizer company;
Sanofi Genzyme;
Tolmar Pharmaceuticals, Inc.
Reproduction Permission
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
AUA Privacy and Confidentiality Policy
www.auanet.org/education/confidentiality-statement.cfm
Contact Information
American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800
CME Information
For all inquiries regarding CME credit email: education@AUAnet.org
Available Credit
- 1.25 AMA PRA Category 1 Credit™
- 1.25 Non-Physician Participation